Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more : results of a multicenter phase 3 study

  • Lo B
  • Beck J
  • Graux C
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Bob Lo

  • Joachim Beck

  • Carlos Graux

  • Wim Van Putten

  • Harry C Schouten

  • Leo F Verdonck

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free